Kentucky Retirement Systems Decreases Stake in DexCom, Inc. (NASDAQ:DXCM)

Kentucky Retirement Systems lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 27,538 shares of the medical device company’s stock after selling 379 shares during the quarter. Kentucky Retirement Systems’ holdings in DexCom were worth $2,142,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter valued at about $25,000. Heck Capital Advisors LLC purchased a new stake in DexCom during the fourth quarter worth approximately $38,000. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the third quarter worth approximately $57,000. Covestor Ltd lifted its stake in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,083 shares of company stock valued at $3,309,794. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several recent analyst reports. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Trading Down 0.6 %

NASDAQ:DXCM opened at $88.78 on Friday. The firm has a market cap of $34.69 billion, a P/E ratio of 62.08, a PEG ratio of 2.30 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock’s 50 day simple moving average is $83.50 and its 200-day simple moving average is $76.06. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.